- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00452387
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
The primary objective of this study is to test the hypothesis that the combination of Mitoxantrone, Prednisone and Sorafenib in taxane-refractory patients with metastatic hormone refractory prostate cancer (mHRPC) will result in an improvement of the median time to progression (TTP). Since the median (i.e 50% of patients) TTP for Mitoxantrone/Prednisone is 3 months, our hypothesis is that 70% will have not progressed at 3 months with this investigational combination. Progression will be assessed by radiologic imaging criteria.
The early stopping point is 21 subjects. If 10 or fewer subjects with tumor favorable response are observed when 21 subjects are accrued then the null hypothesis is accepted and the trial is terminated. If 16 or more subjects with tumor favorable response are observed when 21 subjects are accrued then the alternative hypothesis is accepted and the trial is terminated. The probability of early stopping under the null is 0.51, and under the alternative is 0.39. If the trial progresses until 42 subjects are evaluated and 24 or more subjects with favorable response are observed then the null hypothesis is rejected. This design minimizes the average sample number under the null, which is 31.2.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
La Verne, California, Yhdysvallat, 91750
- Wilshire Oncology Medical Group, Inc.
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30309
- Peachtree Hematology Oncology Consultants
-
Macon, Georgia, Yhdysvallat, 31201
- Central Georgia Cancer Care
-
Marietta, Georgia, Yhdysvallat, 30060
- Northwest Georgia Oncology Centers
-
-
Montana
-
Billings, Montana, Yhdysvallat, 59101
- Hematology Oncology Centers of the Northern Rockies, PC
-
-
Ohio
-
Columbus, Ohio, Yhdysvallat, 43213
- Mid-Ohio Oncology/Hematology, Inc.
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Yhdysvallat, 17605
- Lancaster Cancer Center
-
Philadelphia, Pennsylvania, Yhdysvallat, 19106
- Pennsylvania Oncology Hematmology Associates
-
-
Tennessee
-
Memphis, Tennessee, Yhdysvallat, 38120
- The West Clinic
-
-
Virginia
-
Chesapeake, Virginia, Yhdysvallat, 23320
- Cancer Specialists of Tidewater
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Voluntary written informed consent
- Histopathologic diagnosis of prostatic adenocarcinoma with evidence of progression despite adequate castration (testosterone < 50 ng/dL)
- Progressive disease after taxane-based chemotherapy (docetaxel or paclitaxel, single agent or combination regimens, weekly or every 21 day schedules)
- Patients who discontinued taxane- based chemotherapy because of toxicity will be eligible as long as there is evidence of progressive disease
- Minimum of 4 weeks period from last chemotherapy infusion to registration (this does not apply to steroid use which is permitted). Estramustine needs to be discontinued at least 6 weeks prior to first day of treatment on protocol
- A minimum of 4 weeks off bicalutamide, nilutamide, megestrol acetate ketoconazole, diethylstilbestrol (DES). Minimum of 2 weeks off flutamide
- Reductase inhibitors will be allowed if initiated at least 2 months prior to registration
- No concurrent investigational therapy
- Complementary and Alternative Medicine (CAM) products will be permitted as long as patients have been receiving them for at least 2 months. Initiation of new CAM products while on protocol will be discouraged.
- Ongoing androgen deprivation therapy (orchiectomy, gonadotropin-releasing hormone (GnRH) agonist or antagonist)
Adequate bone marrow, liver and renal function as assessed by the following:
- Hemoglobin ≥ 9.0 g/dl
- Absolute neutrophil count (ANC) ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT and AST ≤ 2.5 times the ULN ( ≤ 5 x ULN for patients with liver involvement)
- Creatinine ≤ 1.5 times the ULN
- International normalized ratio (INR) < 1.5 or a Prothrombin (PT)/Partial thromboplastin time (PTT) within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.
- ECOG performance status ≤ 2
- Baseline left ventricular ejection fraction (LVEF) ≥ 50%
- Life expectancy ≥ 3 months
- Patients must agree to use adequate contraception prior to study entry, during the study and for at least three months after the last administration of sorafenib
Exclusion Criteria:
- More than one line of prior cytotoxic chemotherapy in the metastatic setting, previous adjuvant chemotherapy will be allowed
- No active malignancy other than prostate cancer (except non-melanoma skin cancer) within 5 years of enrollment
- Known brain metastases
- Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA). Patients must not have unstable angina or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- Uncontrolled hypertension
- Active clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
- Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
- Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of study drug
- Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of study drug
- Poorly controlled hyperglycemia
- Treatment with radiotherapy within 4 weeks or treatment with radiopharmaceuticals within past 8 weeks
- Patient has received other investigational drugs within 14 days before enrollment
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Serious non-healing wound or ulcer
- Evidence or history of bleeding diathesis or coagulopathy
- Use of St. John's Wort or rifampin
- Known or suspected allergy to sorafenib or any agent given in the course of this trial
- Any condition that impairs patient's ability to swallow whole pills
- Any malabsorption problem
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Median Time to Progression (TTP) by Imaging
Aikaikkuna: Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
Time to progression is defined as the time from treatment start until objective tumor progression.
The median time to progression is the parameter used to describe TTP.
|
Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Correlation of Biochemical Criteria (PSA, Prostate-specific Antigen) With Objective Imaging
Aikaikkuna: PSA was evaluated on day 1 of every cycle (approximately every 3 weeks) during study treatment. Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
The test of association assesses the null hypothesis that the frequency of PSA response is the same for patients with and without a favorable imaging response.
PSA response required a 50% reduction of the baseline PSA result that was confirmed three weeks later.
Favorable imaging response is defined as stable disease, partial response, or complete response per RECIST guidelines.
The Fisher's exact test was used to test this hypothesis.
|
PSA was evaluated on day 1 of every cycle (approximately every 3 weeks) during study treatment. Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
Quality of Life (QoL)
Aikaikkuna: The Patient Care Monitor questionnaire was administered on day 1 of every cycle (approximately every 3 weeks) during study treatment.
|
The subject answers questions from the following 6 categories: general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation.
Each question has a scale from 0 through 10, where 0 is not a problem and 10 is as bad as possible.
The scores for the 6 categories are combined and normalized, and used to describe overall quality of life.
Because normalized scores are created using a look-up index, there is no clearly defined maximum value.
In practice, the maximum value for the combined scale is 73.5.
|
The Patient Care Monitor questionnaire was administered on day 1 of every cycle (approximately every 3 weeks) during study treatment.
|
Median Overall Survival (OS)
Aikaikkuna: Overall survival was measured from day 1 of treatment until the end of treatment and then every 3 months thereafter until death.
|
Overall survival is defined as the time from treatment start until death from any cause.
The median overall survival time is used to measure OS.
|
Overall survival was measured from day 1 of treatment until the end of treatment and then every 3 months thereafter until death.
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Päätutkija: Vasily Assikis, MD, Peachtree Hematology Oncology Consultants
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Sukuelinten kasvaimet, mies
- Eturauhasen sairaudet
- Eturauhasen kasvaimet
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Ääreishermoston aineet
- Entsyymin estäjät
- Analgeetit
- Aistijärjestelmän agentit
- Tulehdusta ehkäisevät aineet
- Antineoplastiset aineet
- Glukokortikoidit
- Hormonit
- Hormonit, hormonikorvikkeet ja hormoniantagonistit
- Antineoplastiset aineet, hormonaaliset
- Topoisomeraasi II:n estäjät
- Topoisomeraasin estäjät
- Proteiinikinaasin estäjät
- Sorafenibi
- Prednisoni
- Mitoksantroni
Muut tutkimustunnusnumerot
- ACORN AVAHRPC0607
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Metastaattinen eturauhassyöpä
-
Fore BiotherapeuticsRekrytointiCancer sisältää BRAF-muutoksiaYhdysvallat, Saksa, Espanja, Yhdistynyt kuningaskunta, Korean tasavalta, Italia, Ranska, Ruotsi, Kanada
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
Samsung Medical CenterValmisHER2-positiivinen Refractory Advanced CancerKorean tasavalta
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiVaiheen III vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Epäsuoran levyepiteelisyöpä | Stage IVA Vulvar Cancer AJCC v7Yhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiVaiheen II Vulvar Cancer AJCC v8 | Vaiheen IIIC vulvar Cancer AJCC v8 | Stage IVA Vulvar Cancer AJCC v8 | Kolmannen vaiheen ulkosynnyttäjäsyöpä AJCC v8 | Vaihe IIIA Vulvar Cancer AJCC v8 | Vaihe IIIB Vulvar Cancer AJCC v8Yhdysvallat
-
University of UtahNational Cancer Institute (NCI)RekrytointiVäsymys | Istuva elämäntapa | Metastaattinen eturauhassyöpä | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8 | Stage IVB Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8Yhdysvallat
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...ValmisTutki kiinalaisia naisia, jotka eivät ole noudattaneet American Cancer Societyn mammografiaseulontaohjeitaYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ValmisOhutsuolen adenokarsinooma | Vaihe III ohutsuolen adenokarsinooma AJCC v8 | Vaihe IIIA ohutsuolen adenokarsinooma AJCC v8 | Vaihe IIIB ohutsuolen adenokarsinooma AJCC v8 | IV vaiheen ohutsuolen adenokarsinooma AJCC v8 | Vater-adenokarsinooman ampulla | Vaiheen III ampulla Vater Cancer AJCC v8 | Vaiheen... ja muut ehdotYhdysvallat
-
AmgenAktiivinen, ei rekrytointiKRAS p, G12c Mutated / Advanced Metastatic NSCLCSuomi, Yhdysvallat, Kanada, Belgia, Espanja, Korean tasavalta, Alankomaat, Yhdistynyt kuningaskunta, Australia, Tanska, Unkari, Ruotsi, Taiwan, Kreikka, Venäjän federaatio, Sveitsi, Ranska, Italia, Japani, Puola, Brasilia, Saksa, ...
-
Centre Francois BaclesseLigue contre le cancer, FranceRekrytointiPitkäaikaiset syövän sivuvaikutukset | Tukihoito syövän hoidossa | Cancer Survivorship Care Plan | Edistynyt sairaanhoitaja | Lantion gynekologinen syöpäRanska